Cover Image
市場調查報告書

全球偏頭痛藥市場

Global Migraine Market: Industry Analysis & Outlook 2017-2021

出版商 Koncept Analytics 商品編碼 358169
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
全球偏頭痛藥市場 Global Migraine Market: Industry Analysis & Outlook 2017-2021
出版日期: 2017年06月01日 內容資訊: 英文 66 Pages
簡介

本報告提供全球偏頭痛藥市場相關調查分析,以現狀與未來發展預測為焦點,提供市場規模,市場區隔分析,市場動態,加上競爭情形和主要企業等相關的系統性資訊。

第1章 市場概要

  • 簡介
  • 階段
  • 診斷
  • 治療

第2章 全球偏頭痛藥市場分析

  • 全球偏頭痛藥市場:各金額
  • 全球偏頭痛藥市場預測:各金額
  • 全球偏頭痛藥市場:治療藥各類型
  • 全球治療用肉毒桿菌市場預測:各金額
  • 全球治療用肉毒桿菌市場:各適應症

第3章 各地區市場

  • 美國
  • 美國的偏頭痛藥的收益
  • 歐洲

第4章 市場動態

  • 成長推動因素
  • 趨勢
  • 課題

第5章 競爭情形

第6章 企業簡介

  • Amgen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Alder Biopharmaceuticals

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Migraine is a chronic neurovascular disorder characterized by severe recurrent headaches. It is one of the most common and most prevalent disabling neurological conditions, characterized by episodes often called migraine attacks. They are quite different from regular headaches which are non-migrainous. Migraineurs generally have a lower threshold to triggers that might cause neuronal hyperexcitability, including sleep disturbances, environmental or emotional challenges, alcohol exposure, diet, and hormonal cycles/changes, among others. Migraine attacks can cause significant pain for hours to days and can be so severe that the pain is disabling. Migraine headache is typically throbbing, unilateral (one sided), and is aggravated by physical activity. It typically presents with additional symptoms in addition to headache pain, including nausea, and sensitivity to light and/or sound.

Depending on symptoms, migraine is broadly classified into two categories, Chronic and Episodic. Migraines can be treated with two types of drugs: abortive and preventive. Abortive medications are especially useful for people who have nausea or vomiting related to their migraine, and they work quickly. Preventive treatment is considered if migraine occurs frequently, typically more than one migraine per week, or if migraine symptoms are severe.

The global migraine market is set to experience favourable growth driven by factors such as increasing female population & increasing cigarette consumption. Further, the scope of growth for this market will be broadened by rising healthcare expenditure and accelerating economic growth. However, growth of this budding market will be hindered by limitations of current migraine therapies, regulatory challenges and high cost associated with migraine drugs.

The report “Global Migraine Market: Industry Analysis & Outlook (2017-2021)” analyses the development of this market, with focus majorly on the U.S. market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Amgen Inc., Eli Lilly and Company, Teva Pharmaceuticals & Alder Biopharmaceuticals are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global migraine market along with the study of the regional markets.

Table of Contents

1. Overview

  • 1.1. Introduction
  • 1.2. Stages
  • 1.3. Diagnosis
  • 1.4. Treatment

2. Global Market Analysis

  • 2.1. Global Migraine Market by Value
  • 2.2. Global Migraine Market Forecast by Value
  • 2.3. Global Migraine Market by Drug Type
  • 2.4. Global Therapeutic Botulinum Toxin Market Forecast by Value
  • 2.5. Global Therapeutic Botulinum Toxin Market by Indication

3. Regional Market

  • 3.1. The U.S.
    • 3.1.1. The U.S. Total Migraine Population
    • 3.1.2. The U.S. Diagnosed & Treated Adult Migraine Population
    • 3.1.3. The U.S. Migraine Population with CV Risk Factors
    • 3.1.4. The U.S. Migraine Treatment by Specialty
    • 3.1.5. The U.S. Migraine Treated Population by Drug Type
    • 3.1.6. The U.S. Acute Migraine Prescription Volume
  • 3.2. The U.S Migraine Drugs Revenue
    • 3.2.1. The U.S. Cambia Drug Revenue
    • 3.2.2. The U.S. Lasmiditan Drug Revenue & Treated Patients
    • 3.2.3. The U.S. Alder Drug Revenue
  • 3.3. Europe
    • 3.3.1. Europe Total Migraine and Diagnosed Population
  • 3.4. Europe Migraine Drug Revenue
    • 3.4.1. Europe Alder Drug Revenue

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Growing Female Population
    • 4.1.2. Increasing Cigarette Consumption
    • 4.1.3. Rising HealthCare Expenditure
    • 4.1.4. Accelerating Economic Growth
    • 4.1.5. Increasing Prevalence of Headache Disorder
  • 4.2. Key Trends & Development
    • 4.2.1. Drugs Under Pipeline for Migraine
    • 4.2.2. Technological Advancements
    • 4.2.3. Increasing Awareness for Migraine
  • 4.3. Challenges
    • 4.3.1. Limitations of Current Migraine Therapies
    • 4.3.2. Regulatory Challenges
    • 4.3.3. High Cost Associated

5. Competition

  • 5.1. Global Market
    • 5.1.1. Global Migraine Market- Revenue Comparison of Key Companies
    • 5.1.2. Global Migraine Market- Market Cap Comparison of Key Companies

6. Company Profiles

  • 6.1. Amgen Inc.
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Eli Lilly and Company
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Teva Pharmaceuticals
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Alder Biopharmaceuticals
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Types of Migraine
  • Global Migraine Market by Value (2012-2016)
  • Global Migraine Market Forecast by Value (2017-2021)
  • Global Migraine Market by Drug Type (2016)
  • Global Therapeutic Botulinum Toxin Market Forecast by Value (2016-2021)
  • Global Therapeutic Botulinum Toxin Market by Indication (2016)
  • The U.S. Total Migraine Population (2016-2021)
  • The U.S. Diagnosed and Treated Adult Migraine Population (2016-2021)
  • The U.S. Migraine Population with CV Risk Factors (2016-2021)
  • The U.S. Migraine Treatment by Specialty (2016)
  • The U.S. Migraine Treated Population by Drug Type (2016)
  • The U.S. Acute Migraine Prescription Volume (2016-2021)
  • The U.S. Cambia Drug Revenue (2016-2021)
  • The U.S. Lasmiditan Drug Revenue & Treated Patients (2018-2022)
  • The U.S. Alder Drug Revenue (2019-2023)
  • Europe Total Migraine and Diagnosed Population (2016-2021)
  • Europe Alder Drug Revenue (2021-2025)
  • Global Female Population (2012-2016)
  • Global Cigarette Consumption (2000-2016)
  • Global HealthCare Expenditure Per Capita (2012-2016)
  • Global GDP Per Capita (2012-2016)
  • Global Migraine Market-Revenue Comparison of Key Companies (2016)
  • Global Migraine Market- Market Cap Comparison of Key Companies (2016)
  • Amgen Inc. Revenue by Geographic Region (2016)
  • Amgen Inc. Revenue and Net Income (2012-2016)
  • Amgen Inc. Research and Development Expenditure (2014-2016)
  • Eli Lilly and Company Revenue by Segments (2016)
  • Eli Lilly and Company Revenue and Net Income (2012-2016)
  • Eli Lilly and Company Research and Development Expenditure (2014-2016)
  • Teva Pharmaceuticals Revenue by Segments (2016)
  • Teva Pharmaceuticals Revenue and Net Income (2012-2016)
  • Alder Biopharmaceuticals Revenue and Net Income (2012-2016)
  • Alder Biopharmaceuticals Research & Development Expenditure (2014-2016)

List of Tables

  • Stages of Migraine
  • Selected Migraine Drugs Under Development (2016)
  • Alder Pharmaceuticals Pipeline Overview (2016)
Back to Top